198 related articles for article (PubMed ID: 36505498)
1. Integrated profiling uncovers prognostic, immunological, and pharmacogenomic features of ferroptosis in triple-negative breast cancer.
Fang K; Xu Z; Jiang S; Yan C; Tang D; Huang Y
Front Immunol; 2022; 13():985861. PubMed ID: 36505498
[TBL] [Abstract][Full Text] [Related]
2. A novel fatty-acid metabolism-based classification for triple negative breast cancer.
Yang X; Tang W; He Y; An H; Wang J
Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837
[TBL] [Abstract][Full Text] [Related]
3. Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery.
Zou Y; Xie J; Zheng S; Liu W; Tang Y; Tian W; Deng X; Wu L; Zhang Y; Wong CW; Tan D; Liu Q; Xie X
Int J Surg; 2022 Nov; 107():106936. PubMed ID: 36341760
[TBL] [Abstract][Full Text] [Related]
4. An iron metabolism and immune related gene signature for the prediction of clinical outcome and molecular characteristics of triple-negative breast cancer.
Li XF; Fu WF; Zhang J; Song CG
BMC Cancer; 2022 Jun; 22(1):619. PubMed ID: 35668369
[TBL] [Abstract][Full Text] [Related]
5. Ferroptosis Inducers Upregulate PD-L1 in Recurrent Triple-Negative Breast Cancer.
Desterke C; Xiang Y; Elhage R; Duruel C; Chang Y; Hamaï A
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201582
[TBL] [Abstract][Full Text] [Related]
6. Development and Verification of a Prognostic Ferroptosis-Related Gene Model in Triple-Negative Breast Cancer.
Wu S; Pan R; Lu J; Wu X; Xie J; Tang H; Li X
Front Oncol; 2022; 12():896927. PubMed ID: 35719954
[TBL] [Abstract][Full Text] [Related]
7. Ferroptosis and triple-negative breast cancer: Potential therapeutic targets.
Xu N; Li B; Liu Y; Yang C; Tang S; Cho WC; Huang Z
Front Oncol; 2022; 12():1017041. PubMed ID: 36568247
[TBL] [Abstract][Full Text] [Related]
8. Ferroptosis induction via targeting metabolic alterations in triple-negative breast cancer.
Wang Y; Sun Y; Wang F; Wang H; Hu J
Biomed Pharmacother; 2023 Dec; 169():115866. PubMed ID: 37951026
[TBL] [Abstract][Full Text] [Related]
9. Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies.
Liao M; Qin R; Huang W; Zhu HP; Peng F; Han B; Liu B
J Hematol Oncol; 2022 Apr; 15(1):44. PubMed ID: 35414025
[TBL] [Abstract][Full Text] [Related]
10. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
[TBL] [Abstract][Full Text] [Related]
11. Novel molecular insights into pyroptosis in triple-negative breast cancer prognosis and immunotherapy.
Yu B; Luo J; Yang Y; Zhen K; Shen B
J Gene Med; 2024 Jan; 26(1):e3645. PubMed ID: 38041540
[TBL] [Abstract][Full Text] [Related]
12. Ferroptosis: the emerging player in remodeling triple-negative breast cancer.
Li J; He D; Li S; Xiao J; Zhu Z
Front Immunol; 2023; 14():1284057. PubMed ID: 37928550
[TBL] [Abstract][Full Text] [Related]
13. Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy.
Zhou Y; Che Y; Fu Z; Zhang H; Wu H
Front Public Health; 2022; 10():902378. PubMed ID: 35875026
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of cannabinoid receptor type 1 sensitizes triple-negative breast cancer cells to ferroptosis via regulating fatty acid metabolism.
Li P; Lin Q; Sun S; Yang N; Xia Y; Cao S; Zhang W; Li Q; Guo H; Zhu M; Wang Y; Zheng Z; Li S
Cell Death Dis; 2022 Sep; 13(9):808. PubMed ID: 36130940
[TBL] [Abstract][Full Text] [Related]
15. PGM5P3-AS1 regulates MAP1LC3C to promote cell ferroptosis and thus inhibiting the malignant progression of triple-negative breast cancer.
Qi L; Sun B; Yang B; Lu S
Breast Cancer Res Treat; 2022 Jun; 193(2):305-318. PubMed ID: 35325342
[TBL] [Abstract][Full Text] [Related]
16. The molecular subtypes of triple negative breast cancer were defined and a ligand-receptor pair score model was constructed by comprehensive analysis of ligand-receptor pairs.
Pan W; Song K; Zhang Y; Yang C; Zhang Y; Ji F; Zhang J; Shi J; Wang K
Front Immunol; 2022; 13():982486. PubMed ID: 36119101
[TBL] [Abstract][Full Text] [Related]
17. Near-Infrared Phototheranostic Iron Pyrite Nanocrystals Simultaneously Induce Dual Cell Death Pathways via Enhanced Fenton Reactions in Triple-Negative Breast Cancer.
Zhao C; Liu Z; Chang CC; Chen YC; Zhang Q; Zhang XD; Andreou C; Pang J; Liu ZX; Wang DY; Kircher MF; Yang J
ACS Nano; 2023 Mar; 17(5):4261-4278. PubMed ID: 36706095
[TBL] [Abstract][Full Text] [Related]
18. Molecular Characterization and Establishment of a Prognostic Model Based on Primary Immunodeficiency Features in Association with RNA Modifications in Triple-Negative Breast Cancer.
Xia H; Xu X; Guo Y; Deng X; Wang Y; Fu S
Genes (Basel); 2023 Dec; 14(12):. PubMed ID: 38136994
[TBL] [Abstract][Full Text] [Related]
19. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy.
Yang F; Xiao Y; Ding JH; Jin X; Ma D; Li DQ; Shi JX; Huang W; Wang YP; Jiang YZ; Shao ZM
Cell Metab; 2023 Jan; 35(1):84-100.e8. PubMed ID: 36257316
[TBL] [Abstract][Full Text] [Related]
20. Disulfiram/Copper Induce Ferroptosis in Triple-Negative Breast Cancer Cell Line MDA-MB-231.
Chu M; An X; Fu C; Yu H; Zhang D; Li Q; Man X; Dai X; Li Z
Front Biosci (Landmark Ed); 2023 Aug; 28(8):186. PubMed ID: 37664913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
